|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2017-12-14 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2007-03-05 |
|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段撤市 |
|
首次获批日期2008-01-18 |
A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
100 项与 Noden Pharma DAC 相关的临床结果
0 项与 Noden Pharma DAC 相关的专利(医药)
100 项与 Noden Pharma DAC 相关的药物交易
100 项与 Noden Pharma DAC 相关的转化医学